APO Research
Talk to an analyst

APO RESEARCH · REPORT

Intestinal Ascariasis Medicine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Intestinal Ascariasis Medicine Market Outlook and Growth Opportunities 2026

19 December 2025193 pages

Choose your research edition.

Industry ResearchIntestinal Ascariasis Medicine Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Intestinal Ascariasis Medicine Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Intestinal Ascariasis Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Intestinal Ascariasis Medicine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Intestinal Ascariasis Medicine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Intestinal Ascariasis Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Intestinal Ascariasis Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Intestinal Ascariasis Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Intestinal Ascariasis Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Intestinal Ascariasis Medicine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Intestinal Ascariasis Medicine market include Actavis, Bayer HealthCare, Bullvet, Cipla, Endo Pharmaceuticals, Henan Sino New Energy Material, Inject Care Parenterals, Purdue Pharma and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Intestinal Ascariasis Medicine market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Intestinal Ascariasis Medicine and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Intestinal Ascariasis Medicine revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Intestinal Ascariasis Medicine market.

Intestinal Ascariasis Medicine Segment by Company

Actavis

Bayer HealthCare

Bullvet

Cipla

Endo Pharmaceuticals

Henan Sino New Energy Material

Inject Care Parenterals

Purdue Pharma

Pfizer

Novartis

Johnson & Johnson

Sanofi

Sun Pharmaceutical Industries

Intestinal Ascariasis Medicine Segment by Type

Painkiller

Piperazine Citrate

Complication Treatment Drug

Others

Intestinal Ascariasis Medicine Segment by Application

Patients With Ulcer Disease

Complication Treatment

Others

Intestinal Ascariasis Medicine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Intestinal Ascariasis Medicine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Intestinal Ascariasis Medicine key companies, revenue, market share, and recent developments.

3. To split the Intestinal Ascariasis Medicine breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Intestinal Ascariasis Medicine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Intestinal Ascariasis Medicine significant trends, drivers, influence factors in global and regions.

6. To analyze Intestinal Ascariasis Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intestinal Ascariasis Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Intestinal Ascariasis Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intestinal Ascariasis Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Intestinal Ascariasis Medicine industry.

Chapter 3: Detailed analysis of Intestinal Ascariasis Medicine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Intestinal Ascariasis Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Intestinal Ascariasis Medicine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Intestinal Ascariasis Medicine Industry Trends Table 2. Intestinal Ascariasis Medicine Industry Drivers Table 3. Intestinal Ascariasis Medicine Industry Opportunities and Challenges Table 4. Intestinal Ascariasis Medicine Industry Restraints Table 5. Global Intestinal Ascariasis Medicine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Intestinal Ascariasis Medicine Revenue Share by Company (2021-2026) Table 7. Global Intestinal Ascariasis Medicine Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Intestinal Ascariasis Medicine Key Company Manufacturing Base & Headquarters Table 9. Global Intestinal Ascariasis Medicine Company, Product Type & Application Table 10. Global Intestinal Ascariasis Medicine Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Intestinal Ascariasis Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Painkiller Table 15. Significant Companies of Piperazine Citrate Table 16. Significant Companies of Complication Treatment Drug Table 17. Significant Companies of Others Table 18. Global Intestinal Ascariasis Medicine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Intestinal Ascariasis Medicine Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Intestinal Ascariasis Medicine Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Intestinal Ascariasis Medicine Sales Value Share by Type (2021-2026) Table 22. Global Intestinal Ascariasis Medicine Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Patients With Ulcer Disease Table 24. Significant Companies of Complication Treatment Table 25. Significant Companies of Others Table 26. Global Intestinal Ascariasis Medicine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Intestinal Ascariasis Medicine Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Intestinal Ascariasis Medicine Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Intestinal Ascariasis Medicine Sales Value Share by Application (2021-2026) Table 30. Global Intestinal Ascariasis Medicine Sales Value Share by Application (2027-2032) Table 31. Global Intestinal Ascariasis Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Intestinal Ascariasis Medicine Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Intestinal Ascariasis Medicine Sales Value Share by Region (2021-2026) Table 34. Global Intestinal Ascariasis Medicine Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Intestinal Ascariasis Medicine Sales Value Share by Region (2027-2032) Table 36. Global Intestinal Ascariasis Medicine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Intestinal Ascariasis Medicine Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Intestinal Ascariasis Medicine Sales Value Market Share by Country (2021-2026) Table 39. Global Intestinal Ascariasis Medicine Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Intestinal Ascariasis Medicine Sales Value Market Share by Country (2027-2032) Table 41. Actavis Company Information Table 42. Actavis Business Overview Table 43. Actavis Intestinal Ascariasis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Actavis Intestinal Ascariasis Medicine Product Portfolio Table 45. Actavis Recent Development Table 46. Bayer HealthCare Company Information Table 47. Bayer HealthCare Business Overview Table 48. Bayer HealthCare Intestinal Ascariasis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Bayer HealthCare Intestinal Ascariasis Medicine Product Portfolio Table 50. Bayer HealthCare Recent Development Table 51. Bullvet Company Information Table 52. Bullvet Business Overview Table 53. Bullvet Intestinal Ascariasis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Bullvet Intestinal Ascariasis Medicine Product Portfolio Table 55. Bullvet Recent Development Table 56. Cipla Company Information Table 57. Cipla Business Overview Table 58. Cipla Intestinal Ascariasis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Cipla Intestinal Ascariasis Medicine Product Portfolio Table 60. Cipla Recent Development Table 61. Endo Pharmaceuticals Company Information Table 62. Endo Pharmaceuticals Business Overview Table 63. Endo Pharmaceuticals Intestinal Ascariasis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Endo Pharmaceuticals Intestinal Ascariasis Medicine Product Portfolio Table 65. Endo Pharmaceuticals Recent Development Table 66. Henan Sino New Energy Material Company Information Table 67. Henan Sino New Energy Material Business Overview Table 68. Henan Sino New Energy Material Intestinal Ascariasis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Henan Sino New Energy Material Intestinal Ascariasis Medicine Product Portfolio Table 70. Henan Sino New Energy Material Recent Development Table 71. Inject Care Parenterals Company Information Table 72. Inject Care Parenterals Business Overview Table 73. Inject Care Parenterals Intestinal Ascariasis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Inject Care Parenterals Intestinal Ascariasis Medicine Product Portfolio Table 75. Inject Care Parenterals Recent Development Table 76. Purdue Pharma Company Information Table 77. Purdue Pharma Business Overview Table 78. Purdue Pharma Intestinal Ascariasis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Purdue Pharma Intestinal Ascariasis Medicine Product Portfolio Table 80. Purdue Pharma Recent Development Table 81. Pfizer Company Information Table 82. Pfizer Business Overview Table 83. Pfizer Intestinal Ascariasis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Pfizer Intestinal Ascariasis Medicine Product Portfolio Table 85. Pfizer Recent Development Table 86. Novartis Company Information Table 87. Novartis Business Overview Table 88. Novartis Intestinal Ascariasis Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Novartis Intestinal Ascariasis Medicine Product Portfolio Table 90. Novartis Recent Development Table 91. Johnson & Johnson Company Information Table 92. Johnson & Johnson Business Overview Table 93. Johnson & Johnson Intestinal Ascariasis Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Johnson & Johnson Intestinal Ascariasis Medicine Product Portfolio Table 95. Johnson & Johnson Recent Development Table 96. Sanofi Company Information Table 97. Sanofi Business Overview Table 98. Sanofi Intestinal Ascariasis Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Sanofi Intestinal Ascariasis Medicine Product Portfolio Table 100. Sanofi Recent Development Table 101. Sun Pharmaceutical Industries Company Information Table 102. Sun Pharmaceutical Industries Business Overview Table 103. Sun Pharmaceutical Industries Intestinal Ascariasis Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Sun Pharmaceutical Industries Intestinal Ascariasis Medicine Product Portfolio Table 105. Sun Pharmaceutical Industries Recent Development Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Intestinal Ascariasis Medicine Product Image Figure 2. Global Intestinal Ascariasis Medicine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Intestinal Ascariasis Medicine Market Size (2021-2032) & (US$ Million) Figure 4. Global Intestinal Ascariasis Medicine Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Painkiller Image Figure 8. Piperazine Citrate Image Figure 9. Complication Treatment Drug Image Figure 10. Others Image Figure 11. Global Intestinal Ascariasis Medicine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Intestinal Ascariasis Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Intestinal Ascariasis Medicine Sales Value Share by Type (2021-2032) Figure 14. Patients With Ulcer Disease Image Figure 15. Complication Treatment Image Figure 16. Others Image Figure 17. Global Intestinal Ascariasis Medicine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Intestinal Ascariasis Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Intestinal Ascariasis Medicine Sales Value Share by Application (2021-2032) Figure 20. Global Intestinal Ascariasis Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Intestinal Ascariasis Medicine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Intestinal Ascariasis Medicine Sales Value (2021-2032) & (US$ Million) Figure 23. North America Intestinal Ascariasis Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Intestinal Ascariasis Medicine Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Intestinal Ascariasis Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Intestinal Ascariasis Medicine Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Intestinal Ascariasis Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Intestinal Ascariasis Medicine Sales Value (2021-2032) & (US$ Million) Figure 29. South America Intestinal Ascariasis Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Intestinal Ascariasis Medicine Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Intestinal Ascariasis Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Painkiller
  • Piperazine Citrate
  • Complication Treatment Drug
  • Others
Applications
  • Patients With Ulcer Disease
  • Complication Treatment
  • Others
Companies covered
  • Actavis
  • Bayer HealthCare
  • Bullvet
  • Cipla
  • Endo Pharmaceuticals
  • Henan Sino New Energy Material
  • Inject Care Parenterals
  • Purdue Pharma
  • Pfizer
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Sun Pharmaceutical Industries

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Intestinal Ascariasis Medicine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Intestinal Ascariasis Medicine Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Intestinal Ascariasis Medicine Market Dynamics
  1. 2.1 Intestinal Ascariasis Medicine Industry Trends
  2. 2.2 Intestinal Ascariasis Medicine Industry Drivers
  3. 2.3 Intestinal Ascariasis Medicine Industry Opportunities and Challenges
  4. 2.4 Intestinal Ascariasis Medicine Industry Restraints
3 Intestinal Ascariasis Medicine Market by Company
  1. 3.1 Global Intestinal Ascariasis Medicine Company Revenue Ranking in 2025
  2. 3.2 Global Intestinal Ascariasis Medicine Revenue by Company (2021-2026)
  3. 3.3 Global Intestinal Ascariasis Medicine Company Ranking (2024-2026)
  4. 3.4 Global Intestinal Ascariasis Medicine Company Manufacturing Base and Headquarters
  5. 3.5 Global Intestinal Ascariasis Medicine Company Product Type and Application
  6. 3.6 Global Intestinal Ascariasis Medicine Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Intestinal Ascariasis Medicine Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Intestinal Ascariasis Medicine Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Intestinal Ascariasis Medicine Market by Type
  1. 4.1 Intestinal Ascariasis Medicine Type Introduction
  2. 4.1.1 Painkiller
  3. 4.1.2 Piperazine Citrate
  4. 4.1.3 Complication Treatment Drug
  5. 4.1.4 Others
  6. 4.2 Global Intestinal Ascariasis Medicine Sales Value by Type
  7. 4.2.1 Global Intestinal Ascariasis Medicine Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Intestinal Ascariasis Medicine Sales Value by Type (2021-2032)
  9. 4.2.3 Global Intestinal Ascariasis Medicine Sales Value Share by Type (2021-2032)
5 Intestinal Ascariasis Medicine Market by Application
  1. 5.1 Intestinal Ascariasis Medicine Application Introduction
  2. 5.1.1 Patients With Ulcer Disease
  3. 5.1.2 Complication Treatment
  4. 5.1.3 Others
  5. 5.2 Global Intestinal Ascariasis Medicine Sales Value by Application
  6. 5.2.1 Global Intestinal Ascariasis Medicine Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Intestinal Ascariasis Medicine Sales Value by Application (2021-2032)
  8. 5.2.3 Global Intestinal Ascariasis Medicine Sales Value Share by Application (2021-2032)
6 Intestinal Ascariasis Medicine Regional Value Analysis
  1. 6.1 Global Intestinal Ascariasis Medicine Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Intestinal Ascariasis Medicine Sales Value by Region (2021-2032)
  3. 6.2.1 Global Intestinal Ascariasis Medicine Sales Value by Region: 2021-2026
  4. 6.2.2 Global Intestinal Ascariasis Medicine Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Intestinal Ascariasis Medicine Sales Value (2021-2032)
  7. 6.3.2 North America Intestinal Ascariasis Medicine Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Intestinal Ascariasis Medicine Sales Value (2021-2032)
  10. 6.4.2 Europe Intestinal Ascariasis Medicine Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Intestinal Ascariasis Medicine Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Intestinal Ascariasis Medicine Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Intestinal Ascariasis Medicine Sales Value (2021-2032)
  16. 6.6.2 South America Intestinal Ascariasis Medicine Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Intestinal Ascariasis Medicine Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Intestinal Ascariasis Medicine Sales Value Share by Country, 2025 VS 2032
7 Intestinal Ascariasis Medicine Country-level Value Analysis
  1. 7.1 Global Intestinal Ascariasis Medicine Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Intestinal Ascariasis Medicine Sales Value by Country (2021-2032)
  3. 7.2.1 Global Intestinal Ascariasis Medicine Sales Value by Country (2021-2026)
  4. 7.2.2 Global Intestinal Ascariasis Medicine Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Intestinal Ascariasis Medicine Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Intestinal Ascariasis Medicine Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Intestinal Ascariasis Medicine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Actavis
  2. 8.1.1 Actavis Company Information
  3. 8.1.2 Actavis Business Overview
  4. 8.1.3 Actavis Intestinal Ascariasis Medicine Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Actavis Intestinal Ascariasis Medicine Product Portfolio
  6. 8.1.5 Actavis Recent Developments
  7. 8.2 Bayer HealthCare
  8. 8.2.1 Bayer HealthCare Company Information
  9. 8.2.2 Bayer HealthCare Business Overview
  10. 8.2.3 Bayer HealthCare Intestinal Ascariasis Medicine Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer HealthCare Intestinal Ascariasis Medicine Product Portfolio
  12. 8.2.5 Bayer HealthCare Recent Developments
  13. 8.3 Bullvet
  14. 8.3.1 Bullvet Company Information
  15. 8.3.2 Bullvet Business Overview
  16. 8.3.3 Bullvet Intestinal Ascariasis Medicine Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bullvet Intestinal Ascariasis Medicine Product Portfolio
  18. 8.3.5 Bullvet Recent Developments
  19. 8.4 Cipla
  20. 8.4.1 Cipla Company Information
  21. 8.4.2 Cipla Business Overview
  22. 8.4.3 Cipla Intestinal Ascariasis Medicine Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Cipla Intestinal Ascariasis Medicine Product Portfolio
  24. 8.4.5 Cipla Recent Developments
  25. 8.5 Endo Pharmaceuticals
  26. 8.5.1 Endo Pharmaceuticals Company Information
  27. 8.5.2 Endo Pharmaceuticals Business Overview
  28. 8.5.3 Endo Pharmaceuticals Intestinal Ascariasis Medicine Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Endo Pharmaceuticals Intestinal Ascariasis Medicine Product Portfolio
  30. 8.5.5 Endo Pharmaceuticals Recent Developments
  31. 8.6 Henan Sino New Energy Material
  32. 8.6.1 Henan Sino New Energy Material Company Information
  33. 8.6.2 Henan Sino New Energy Material Business Overview
  34. 8.6.3 Henan Sino New Energy Material Intestinal Ascariasis Medicine Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Henan Sino New Energy Material Intestinal Ascariasis Medicine Product Portfolio
  36. 8.6.5 Henan Sino New Energy Material Recent Developments
  37. 8.7 Inject Care Parenterals
  38. 8.7.1 Inject Care Parenterals Company Information
  39. 8.7.2 Inject Care Parenterals Business Overview
  40. 8.7.3 Inject Care Parenterals Intestinal Ascariasis Medicine Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Inject Care Parenterals Intestinal Ascariasis Medicine Product Portfolio
  42. 8.7.5 Inject Care Parenterals Recent Developments
  43. 8.8 Purdue Pharma
  44. 8.8.1 Purdue Pharma Company Information
  45. 8.8.2 Purdue Pharma Business Overview
  46. 8.8.3 Purdue Pharma Intestinal Ascariasis Medicine Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Purdue Pharma Intestinal Ascariasis Medicine Product Portfolio
  48. 8.8.5 Purdue Pharma Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Intestinal Ascariasis Medicine Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Intestinal Ascariasis Medicine Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Novartis
  56. 8.10.1 Novartis Company Information
  57. 8.10.2 Novartis Business Overview
  58. 8.10.3 Novartis Intestinal Ascariasis Medicine Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Novartis Intestinal Ascariasis Medicine Product Portfolio
  60. 8.10.5 Novartis Recent Developments
  61. 8.11 Johnson & Johnson
  62. 8.11.1 Johnson & Johnson Company Information
  63. 8.11.2 Johnson & Johnson Business Overview
  64. 8.11.3 Johnson & Johnson Intestinal Ascariasis Medicine Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Johnson & Johnson Intestinal Ascariasis Medicine Product Portfolio
  66. 8.11.5 Johnson & Johnson Recent Developments
  67. 8.12 Sanofi
  68. 8.12.1 Sanofi Company Information
  69. 8.12.2 Sanofi Business Overview
  70. 8.12.3 Sanofi Intestinal Ascariasis Medicine Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sanofi Intestinal Ascariasis Medicine Product Portfolio
  72. 8.12.5 Sanofi Recent Developments
  73. 8.13 Sun Pharmaceutical Industries
  74. 8.13.1 Sun Pharmaceutical Industries Company Information
  75. 8.13.2 Sun Pharmaceutical Industries Business Overview
  76. 8.13.3 Sun Pharmaceutical Industries Intestinal Ascariasis Medicine Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Sun Pharmaceutical Industries Intestinal Ascariasis Medicine Product Portfolio
  78. 8.13.5 Sun Pharmaceutical Industries Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst